Shares of NMC Health are down almost 43%! Should investors buy the dip?

A bombshell shortsellers report raises serious questions about the health of NMC Health (LON: NMC).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shareholders of Abu Dhabi-based NMC Health (LSE: NMC) have been on a rollercoaster ride over the last few years. Between August 2016 and August 2018, the stock rocketed up from 1,200p a share to 4,060p a share. Since August 2018, the share price had see-sawed up and down, settling around 2,500p a share. Then, on December 17, Muddy Waters, a well-known short selling firm, released a damning report alleging that NMC has seriously overstated its financial position, causing the share price to plunge by almost 43%. Do the allegations have any weight to them? Let’s dig in.

What are the accusations?

Let’s get a sense for what Muddy Waters is accusing NMC of. Firstly, the research firm is claiming that it significantly overpaid for the construction of Brightpoint Royal Women’s Hospital. Instead of the estimated $3,500 to $4,000/m2 it should have taken (according to Muddy Waters), the project took $7,700/m2.  

Secondly, Muddy Waters said that NMC significantly overpaid for the purchase of a 70% stake in Premier Care Home Medical and Health Care LLC. $36.4m (£28m) was paid for a business with just 10 employees, and very little in the way of real assets — 91% of the acquisition price was for intangible assets. Unverified accounts state that Premier Care has treated only 60 patients over the last two years, and that it occupies a very small office space.

Muddy Waters also has concerns about NMC’s cash balance and margins, among other issues. The report is extensive and draws on a number of sources, both those publicly available and private intelligence carried out by the firm. Unsurprisingly, NMC denies any wrongdoing, calling the report “false and misleading“. In a response to Muddy Waters, NMC management has said that the higher-than-expected Brightpoint costs represent factors relating to things like floor weight and cladding, and that the Premier Care acquisition was carried out using due diligence from a “Big 4 accounting firm“.

Investor’s verdict

As my colleague Alan Oscroft notes, NMC is one of the most heavily-shorted companies in the FTSE 100. Clearly, it’s not just Muddy Waters that thinks that it might be overvalued. Of course, it is impossible to know right now whether NMC is guilty of the things that it has been accused of.  

As an individual investor, you are frequently going to have an informational disadvantage against the large professionals who have the capital and time to dedicate to an in-depth investigation into a company. Therefore, you should make the most of the data available to you — paying close attention to the short interest, for instance. In my personal experience, it’s rare that short sellers go after a company that doesn’t have issues. Muddy Waters has a strong track record of uncovering such issues in companies in developing economies, most notably in China. I would give NMC a wide berth for now until we have more information.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Stepan Lavrouk owns no stocks mentioned. The Motley Fool UK owns shares of and has recommended NMC Health. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »